recently investigated the vital role of m6A modification and the METTL14/BPTF axis in the epigenetic and metabolic remodeling of metastasis of renal cell carcinoma, highlighting the BPTF inhibitor-AU1 as a key therapeutic candidate (44). Here, METTL14 is linked to renal cell carcinoma.